Answers are grounded in this paper and cite their sources.
Evaluates immunoglobulins' effect on amyloid beta transport in vitro, suggesting implications for Alzheimer's treatment.
Since passive immunization with serum-derived immunoglobulins (intravenous immunoglobulins) showed several positive effects in some patients with Alzheimer's disease (AD), intravenous immunoglobulins (IVIG) are discussed as a possible treatment option. IVIG, an antibody product derived from human plasma, contains natural antibodies against amyloid β(Aβ) peptide. Until now it is not known, how IVIG interferes with pathogenesis in AD, but several proposed mechanisms are in discussion. Receptor types which are involved in transport processes at the BBB are LRP, RAGE and hFcRn. We were looking for an in vitro BBB model expressing these receptors and studied the alteration of transport of Aβ peptides across this model under the influence of immunoglobulins. Cell line ECV304 was found to be suitable for our experiments. We found evidence for involvement of an improved clearance of Aβ across the BBB as well as a decreased Aβ influx from blood to the brain probably following complex formation of immunoglobulins with free Aβ in the periphery. Furthermore, we were able to confirm the activity of IVIG preparations which acted the same way but showed slightly less efficacy in comparison to monoclonal anti-Aβ antibodies. Based on these results we suggest multiple mechanisms responsible for the efficacy of immunotherapy in Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
Poetsch et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: